No, yearly retinal screening and podiatry review are NOT routinely necessary for patients in the prediabetes range.
For patients who have improved from diabetes to prediabetes, routine annual retinal screening and podiatry review are not indicated by current guidelines, which specifically recommend these screenings only for patients with diagnosed diabetes, not prediabetes.
Retinal Screening in Prediabetes
The most recent ADA guidelines 1 clearly state that retinal screening is recommended for:
- Type 1 diabetes: Initial exam within 5 years of diagnosis, then annually
- Type 2 diabetes: Initial exam at diagnosis, then annually (or every 1-2 years if no retinopathy and good glycemic control)
Prediabetes is notably absent from these screening recommendations 2, 3, 1. The guidelines consistently specify screening intervals only for patients with diagnosed diabetes, not those in the prediabetic range.
Evidence on Retinopathy in Prediabetes
While emerging research shows that retinopathy can occur in prediabetes—with prevalence ranging from 0.3-14.1% 4—this has not yet translated into guideline-recommended screening protocols. Recent studies suggest:
- Retinopathy prevalence in prediabetes is approximately 4.1-10.1% 5, 6
- The ADA HbA1c criteria (5.7-6.4%) identify more retinopathy than stricter criteria 6
- However, no major guideline currently recommends routine retinal screening for prediabetes 7
Important caveat: If your patient had documented diabetic retinopathy before improving to prediabetes, they should continue ophthalmologic surveillance as the retinopathy itself requires monitoring regardless of current glycemic status.
Podiatry Review in Prediabetes
Similarly, annual comprehensive foot examinations are recommended only for patients with diabetes 2, 8, 2. The ADA guidelines 8 specify that foot examinations should:
- Be performed annually in all patients with diabetes
- Include inspection, pulse assessment, and loss of protective sensation testing
- Be performed at every visit for those with prior ulceration or sensory loss
Prediabetes is not included in these foot screening recommendations.
Recent research does show early neuropathy can occur in prediabetes (7.8% prevalence) 5, but this has not resulted in guideline changes recommending routine podiatry screening for this population.
Clinical Approach for Your Patient
For a patient now in the prediabetes range:
Focus on preventing progression: Intensive lifestyle intervention and consideration of metformin if high-risk features present 9, 10
Monitor glycemic status: Regular HbA1c monitoring (typically every 3-6 months) to ensure they remain in prediabetes range and don't progress back to diabetes
Resume diabetes screening protocols if they progress back: If HbA1c rises to diabetic range (≥6.5%), reinitiate annual retinal and foot examinations
Consider screening if symptomatic: If the patient develops visual symptoms or foot problems, evaluate regardless of glycemic status
Address cardiovascular risk factors: Hypertension and dyslipidemia management remain important, as these are associated with microvascular changes even in prediabetes 5
Key Pitfall to Avoid
Don't confuse "prediabetes can have microvascular changes" (which is true based on research 5, 6, 4, 11) with "prediabetes requires routine microvascular screening" (which is not supported by current guidelines). The research is evolving, but guideline committees have not yet incorporated prediabetes into routine retinal or podiatry screening protocols 12, 7.
The exception is if your patient had established diabetic complications before improving to prediabetes—those complications require continued monitoring based on their severity, not the current glycemic status.